Navigation Links
Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents
Date:1/28/2010

AMSTERDAM, January 28 /PRNewswire-FirstCall/ -- Elsevier announced today that Scopus Custom Data, the underlying source of Scopus.com, the world's largest abstract and citation database, was chosen by Japan Science and Technology (JST) to conduct citation linkage analysis between scientific articles and patents. JST, as the funding agency for promoting innovation and providing research support to many organizations from industry and academia, selected Scopus Custom Data because it provides wider coverage and clear relations between authors and their affiliations.

According to a paper published by JST in the January edition of Journal of Information Processing and Management , an analysis of research papers cited in patents, shows the linkage between Japan's scientific articles and technology is increasing every year and enabling Japan to maintain its international competitiveness. It has also become clear that research papers written by researchers funded by JST are having greater effects on technology every year; and that JST is playing the political role of promoting the creation of innovation as a funding agency. For details of the published research paper, please refer to the website of Journal of Information Processing and Management http://www.jstage.jst.go.jp/article/johokanri/52/10/52_601/_article/-char/ja/ . The analysis was conducted by using the integrated search system for research papers and patents developed by JST. JST plans to introduce this system at the American Association for the Advancement of Science (AAAS) 2010 Annual Meeting, to be held from February 18 to 22, 2010 in San Diego, USA.

"Nowadays, there are needs to draw up policies for evidence-based scientific technology and innovation, and to construct systems to measure and evaluate them. JST has also began investigations toward achieving the measurement of scientific technology and innovation; and as part of those investigations, by analyzing the state of funding, research papers and patents, JST is seeing influences that return on investment and science have on technology. We selected Scopus Custom Data as the underlying database for our analysis because it provides citation information, a large amount of data, and clear relations between authors and their affiliations," commented Mari Jibu of JST's Research Institute of Science and Technology for Society.

"Attention is being placed on citations in patents as a new index to measure the influence of scientific articles. JST used Scopus data for its analysis on the return on investment of science and technology policies. We are honored to be able to cooperate with JST in this way, and will continue to provide support from now on," added Niels Weertman, Director, Performance & Planning and Collaboration Tools for Elsevier.

About Japan Science and Technology Agency (JST)

Japan Science and Technology Agency (JST) aims to establish Japan as a nation built on the creativity of science and technology and innovation, as a core organization for implementing Japan's science and technology policy in line with the objectives of the Science and Technology Basic Plan. JST's mission is to promote science and technology in Japan by conducting a broad range of activities, including the following:

* Promotion of consistent research and development from basic research to commercialization with particular emphasis on the creation of new technological seeds

* Upgrading the infrastructure for the promotion of science and technology, including dissemination of scientific and technological information

For more information, please visit http://www.jst.go.jp/EN/index.html.

About Scopus.com and Scopus Custom Data

Covering the world's research literature, Scopus.com is the largest abstract and citation database of peer-reviewed literature and quality web sources with smart tools to track, analyze and visualize research. Its unique database contains abstracts and references from 18,000 peer-reviewed journals from more than 5,000 publishers worldwide, ensuring broad interdisciplinary coverage. In addition, Scopus not only offers users citation information about the articles covered, but also integrates web and patent searches directly from its clean and simple interface. Direct links to full-text articles, library resources and other applications like reference management software, make Scopus quicker, easier and more comprehensive to use than any other literature research tool. For more information about Scopus please visit http://www.info.scopus.com

Scopus Custom Data provides research agencies, institutions and government bodies with customized datasets in XML format for large-scale research performance analysis. Scopus Custom Data extracts Scopus core records in accordance to each customer's individual specifications, such as date range, subject categories and geographic location. The XML data can then be loaded by customers into their proprietary in-house systems, making it possible for them to run their specific search queries and execute their own analytical techniques; providing the analyst with the freedom to formulate their own reports. It empowers them to make well-informed, unbiased resource allocation and policy making decisions.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact:
    Nami Kanda
    Elsevier
    +81-35561-5069
    n.kanda@elsevier.com

SOURCE Elsevier


'/>"/>
SOURCE Elsevier
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
2. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
6. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
7. NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan
8. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
9. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
Breaking Biology Technology:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):